Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Paradigm Health Secures $78Million Series B to Expand Clinical Trials
Paradigm Health, the technology company rebuilding the clinical research ecosystem, announced an oversubscribed $78 million Series B financing. The round was led by ARCH Venture Partners, with participation from new investor DFJ Growth and existing investors F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, the American Cancer Society’s BrightEdge Fund, and others, several of whom took super pro-rata positions.
Dario Digital Platform Shows Strong, Lasting BP Improvements
DarioHealth Corp., a global digital health company, announced the publication of new research in JMIR Cardio showing that personalized nudges delivered through its digital platform can lead to meaningful and lasting improvements in blood pressure. The study, titled The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study, used real-world data from individuals using Dario’s platform and compared outcomes for people who received targeted messages with a similar group that did not receive them.
PAICON Advances Global Cancer AI With Diverse Data
The gap in data diversity has long been one of the most serious weaknesses in modern medicine, particularly in oncology, where clinical decisions often depend on patterns found in large datasets. PAICON, a young healthtech company rooted in artificial intelligence and cancer research, has stepped directly into this problem with the goal of building cancer diagnostics that work for the entire world rather than only for the populations that existing models tend to reflect. According to Dr Manasi A Ratnaparkhe, CEO and co founder of PAICON, most cancer AI systems presently rely on datasets drawn primarily from Western countries, which cover only a small portion of the global population. She explains that the majority of people worldwide remain unrepresented, and that this lack of diversity contributes to missed diagnoses and avoidable harm. She describes PAICON’s mission as an effort to correct this imbalance and bring more fairness and accuracy to cancer diagnostics.
GE HealthCare Launches Imaging 360 Powered By AI to Improve Operations Efficiency
GE HealthCare has introduced the latest updates to its Imaging 360 platform, now enhanced with artificial intelligence designed to improve efficiency in radiology departments. The AI-powered Discoveries feature helps balance device usage, optimize scheduling, and identify opportunities to standardize imaging protocols. These advancements aim to give healthcare teams more time and energy to focus on patient care, enabling hospitals to serve more patients effectively with existing resources.
Bayer Launches Phase III Mirena Study for Endometrial Hyperplasia
Bayer has announced the initiation of the Phase III SUNFLOWER study, designed to assess the safety and effectiveness of the 52mg levonorgestrel-releasing intrauterine system Mirena for treating nonatypical endometrial hyperplasia in women. Nonatypical endometrial hyperplasia is a condition where the lining of the uterus becomes abnormally thick due to an imbalance of estrogen and progesterone. The cells in this condition do not show cancerous changes, but women may experience heavy, irregular, or postmenopausal bleeding, and if left untreated, the condition can increase the risk of uterine cancer. Approximately 121 women per 100,000 develop NAEH each year, and currently, there are no approved medical treatments available, creating a significant unmet need.
Elevance Health Enhances Care with Personalization and Service
Saurabh Tandon, Chief Experience Officer at Elevance Health, discussed how the company is reimagining healthcare by learning from consumer-focused industries such as streaming services and creating a more personalized experience for each member. He explained that the future of healthcare involves anticipating consumer needs, addressing issues promptly, and building long-term relationships. Unlike entertainment, healthcare requires an even deeper level of personalization because it is highly personal and trust is essential. Elevance Health earns that trust by providing convenient, flexible support through mobile chat, seamless claim management, easier provider searches, and simplified billing and prescription services while keeping data secure.
Johnson & Johnson Gets EU Approval for IMAAVY to Treat Generalized MG
Johnson & Johnson announced that the European Commission has approved a Marketing Authorisation for IMAAVY (nipocalimab), a fully human FcRn-blocking monoclonal antibody, as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG). gMG is a chronic, incurable autoantibody disease that causes debilitating symptoms such as muscle weakness, difficulty chewing, swallowing and speaking. This approval is for the treatment of a broad population of people living with gMG including adults and adolescent patients 12 years of age and older who are anti-acetylcholine receptor [AChR] or anti-muscle-specific kinase [MuSK] antibody-positive.
HeartBeam Updates FDA Path for 12-Lead ECG Software
HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, announced its regulatory strategy following receipt of a Not Substantially Equivalent (NSE) decision on the Company’s 510(k) submission for its 12-lead Electrocardiogram (ECG) Synthesis Software.
Foundation Health and Amazon Pharmacy Enable Real-Time Prices
Foundation Health, a healthcare technology company that delivers AI-powered infrastructure for pharmacy operations, care coordination, and direct-to-patient delivery, announced a collaboration with Amazon Pharmacy to bring real-time prescription price transparency to customers. Through an API integration with Amazon Pharmacy, Foundation Health customers can now display real-time Amazon Pharmacy pricing and fulfillment options directly within their digital workflows, helping patients avoid surprise costs and improve medication adherence.
GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models
A.D.A.M. Innovations Co. , Japan’s leading AI-driven genomics company, announced the release of three new first-of-their-kind cancer prediction models for its GeneLife GeneAI Forecast platform: breast cancer (women), prostate cancer (men), and pancreatic cancer (unisex), developed using the largest Japanese population genetic database built by the company over 22 years of operation, improving relevance compared with western-derived tools.
Avantor Appoints Sanjeev Mehra to its Board of Directors
Avantor, Inc, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.
To share your insights, please write to us at sudipto@intentamplify.com
